Enveric BiosciencesENVB
13F holders, Q3 2024 (September 30)17holders
4new positions
4sold out
1famous investor
$0.47avg. 13F price*
At the end of Q3 2024, 17 institutions reported holding Enveric Biosciences Inc. (ENVB) in their 13F filings, unchanged from Q2 2024. 4 opened new positions and 4 sold out. The largest holders were AdvisorShares Investments LLC ($174K), Geode Capital Management, LLC ($103K) and Two Sigma Securities, LLC ($15K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Enveric Biosciences Inc.
- CUSIP
- 29405E208
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $12K |
| Exits | 4 | $6K |
All 13F filers, Q2 2024 → Q3 2024: 280,067 shares bought and 53,979 shares sold, net +226,088 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| AdvisorShares Investments LLC | 0.03% | Add +15.8% | 367,047 | $174K |
| Geode Capital Management, LLC | 0.00% | Add +387.9% | 217,893 | $103K |
| Two Sigma Securities, LLC | 0.00% | Add +101.0% | 30,632 | $15K |
| Virtu Financial LLC | 0.00% | Add +67.6% | 23,117 | $11K |
| Vanguard Group Inc. | 0.00% | No change | 18,198 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +51.6% | 17,372 | $8K |
| Two Sigma Investments, LP | 0.00% | New | 13,385 | $6K |
| Citadel Advisors | 0.00% | New | 12,753 | $6K |
| BlackRock, Inc. | 0.00% | — | 9,010 | $4K |
| UBS Group AG | 0.00% | Reduce -98.3% | 731 | $346 |
| Osaic Holdings, Inc. | 0.00% | Reduce -6.5% | 575 | $271 |
| Group One Trading LLC | 0.00% | No change | 273 | $129 |
| Bank of America Corp. | 0.00% | Add +5.5% | 173 | $82 |
| National Bank of Canada | 0.00% | Add +1.4% | 71 | $34 |
| Avior Wealth Management, LLC | 0.00% | New | 50 | $23 |
| Wells Fargo & Company | 0.00% | No change | 16 | $8 |
| Hantz Financial Services, Inc. | 0.00% | New | 1 | $0 |
"% of holder's portfolio" is ENVB's weight in each manager's 13F, not the share of Enveric Biosciences Inc. the manager owns.